1Bavinck IN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queens land, Australia: a follow-up study [ J ]. Transplantation, 1996,61 ( 5 ) : 715-721.
2Euvard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation [ J ]. N Engl J Med, 2003, 348 ( 17 ) : 1681-1691.
3Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience [ J ]. Cancer, 1999, 85 ( 8 ) : 1758-1764.
4Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients : a single-center study [ J ]. Transplant Proc, 1998,30(4) : 1124-1126.
5Martinez J, Otley C, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients [ J ]. Arch Dermatol,2003,139 (3) : 301-306.
6Sheil AG, Disney AP, Mathew TH, et al . De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation[ J]. Transplant Proc, 1993,25 ( 1 ) : 1383-1384.
7Catena F, Nardo B, d'AI'cangelo L, et al. De novo malignancies after organ transplantation [ J ]. Transplant Proc , 2001,33 (1-2) : 1858-1859.
8Vial T, Descotes J. Immunosuppressive drugs and cancer [ J]. Toxicology,2003,185 ( 3 ) :229-240.
9Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients [ J ]. N Engl J Med, 1990, 323 (25) :1723-1728.
10Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk lymphoproliferative disorder [ J ]. Clin Infect Dis, 1995,20 (5) : 1346-1353.
